MLN2480

DRUG2 trials

Sponsors

Millennium Pharmaceuticals, Inc.

Conditions

Advanced Nonhematologic MalignanciesMelanomaMetastatic MelanomaNeoplasmSolid Tumor

Phase 1

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

CompletedNCT01425008

Millennium Pharmaceuticals, Inc.Melanoma, Metastatic Melanoma, Neoplasm +1

Start: 2011-09-15End: 2018-10-16Updated: 2020-08-10

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

CompletedNCT02327169

Millennium Pharmaceuticals, Inc.Advanced Nonhematologic Malignancies

Start: 2015-01-14End: 2018-07-02Updated: 2020-02-25

Related Papers

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

2023-05-2327 citations

A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2015-05-201 citations